Teichmann Sarah A.
CIK: 0002030916
Associated companies
Transaction History
| TXG | ▼ Sell | Open Market | 2,273 | $130K | 8/14/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 5,278 | $302K | 8/13/2026 | View on chart |
| TXG | ▲ Buy | Grant | 8,829 | $0 | 6/4/2026 | View on chart |
| TXG | ▼ Sell | Open Market | 7,579 | $147K | 2/25/2026 | View on chart |
| TXG | ▲ Buy | Grant | 15,357 | $0 | 6/3/2025 | View on chart |
| TXG | ▲ Buy | Grant | 19,002 | $0 | 8/30/2024 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
10x Genomics Partners With Fred Hutchinson Cancer Center
10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.
10x Genomics Partners With Fred Hutchinson Cancer Center. 10x Genomics announced a new collaboration with the Fred Hutchinson Cancer Center to apply single-cell and spatial technologies to solid tumors and blood cancers. This partnership aims to advance research in hematologic malignancies. Separately, Barclays raised its price target for the stock to $110, reflecting continued analyst interest in the company's growth potential.